A European multicentre drug utilisation study of the impact of regulatory measures on prescribing of codeine for pain in children

Karin Hedenmalm (Lead / Corresponding author), Kevin Blake, Katherine Donegan, Miguel Angel Macia, Miguel Gil, Julie Williams, Dolores Montero, Gianmario Candore, Daniel Morales, Xavier Kurz, Peter Arlett

Research output: Contribution to journalArticle

4 Downloads (Pure)

Abstract

Purpose: In June 2013, following recommendations from the World Health Organization (WHO) and Food and Drug Administration (FDA), the European Medicines Agency agreed updates to the codeine product information regarding use for pain in children younger than 12 years and children undergoing tonsillectomy or adenoidectomy (TA) for obstructive sleep apnoea. This study was conducted to (a) assess effectiveness of these measures on codeine prescribing in the “real-world” setting and (b) test feasibility of a study using a common protocol by regulators with access to databases.

Methods: The study was performed using BIFAP (Spain), CPRD (UK), and IMS® Disease Analyzer (France and Germany) databases. Prescribers included general practitioners (GPs) (France and UK), GPs and paediatricians together (Spain), and GPs, paediatricians, and ear, nose, and throat (ENT) specialists separately (Germany). Between January 2010 and June 2015, prevalence of codeine prescribing was obtained every 6 months, and a time series analysis (joinpoint) was performed. Codeine prescribing within ±30 days of TA was also identified. Furthermore, doses, durations, and prior prescribing of other analgesics were investigated.

Results: Over the 5-year period, codeine prescribing decreased in children younger than 12 years (by 84% in France and Spain, 44% in GP practices in Germany, and 33% in the United Kingdom). The temporal pattern was compatible with the regulatory intervention in France and the United Kingdom, whereas a decrease throughout the study period was seen in Germany and Spain. Decreased prescribing associated with TA was suggested in ENT practices in Germany.

Conclusions: Codeine prescribing for children decreased in line with introduced regulatory measures. Multidatabase studies assessing impact of measures by EU regulators are feasible.

Original languageEnglish
Number of pages11
JournalPharmacoepidemiology and Drug Safety
Early online date20 Jun 2019
DOIs
Publication statusE-pub ahead of print - 20 Jun 2019

Fingerprint

Drug Utilization
Codeine
Germany
Adenoidectomy
Pain
Spain
General Practitioners
France
Tonsillectomy
Pharynx
Nose
Ear
Databases
Feasibility Studies
Obstructive Sleep Apnea
United States Food and Drug Administration
General Practice
Analgesics

Keywords

  • children
  • codeine
  • drug utilization
  • pharmacoepidemiology
  • risk minimization measures

Cite this

Hedenmalm, Karin ; Blake, Kevin ; Donegan, Katherine ; Macia, Miguel Angel ; Gil, Miguel ; Williams, Julie ; Montero, Dolores ; Candore, Gianmario ; Morales, Daniel ; Kurz, Xavier ; Arlett, Peter. / A European multicentre drug utilisation study of the impact of regulatory measures on prescribing of codeine for pain in children. In: Pharmacoepidemiology and Drug Safety. 2019.
@article{d074294264d743b1b3bbe6462c291735,
title = "A European multicentre drug utilisation study of the impact of regulatory measures on prescribing of codeine for pain in children",
abstract = "Purpose: In June 2013, following recommendations from the World Health Organization (WHO) and Food and Drug Administration (FDA), the European Medicines Agency agreed updates to the codeine product information regarding use for pain in children younger than 12 years and children undergoing tonsillectomy or adenoidectomy (TA) for obstructive sleep apnoea. This study was conducted to (a) assess effectiveness of these measures on codeine prescribing in the “real-world” setting and (b) test feasibility of a study using a common protocol by regulators with access to databases.Methods: The study was performed using BIFAP (Spain), CPRD (UK), and IMS{\circledR} Disease Analyzer (France and Germany) databases. Prescribers included general practitioners (GPs) (France and UK), GPs and paediatricians together (Spain), and GPs, paediatricians, and ear, nose, and throat (ENT) specialists separately (Germany). Between January 2010 and June 2015, prevalence of codeine prescribing was obtained every 6 months, and a time series analysis (joinpoint) was performed. Codeine prescribing within ±30 days of TA was also identified. Furthermore, doses, durations, and prior prescribing of other analgesics were investigated.Results: Over the 5-year period, codeine prescribing decreased in children younger than 12 years (by 84{\%} in France and Spain, 44{\%} in GP practices in Germany, and 33{\%} in the United Kingdom). The temporal pattern was compatible with the regulatory intervention in France and the United Kingdom, whereas a decrease throughout the study period was seen in Germany and Spain. Decreased prescribing associated with TA was suggested in ENT practices in Germany.Conclusions: Codeine prescribing for children decreased in line with introduced regulatory measures. Multidatabase studies assessing impact of measures by EU regulators are feasible.",
keywords = "children, codeine, drug utilization, pharmacoepidemiology, risk minimization measures",
author = "Karin Hedenmalm and Kevin Blake and Katherine Donegan and Macia, {Miguel Angel} and Miguel Gil and Julie Williams and Dolores Montero and Gianmario Candore and Daniel Morales and Xavier Kurz and Peter Arlett",
year = "2019",
month = "6",
day = "20",
doi = "10.1002/pds.4836",
language = "English",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "Wiley",

}

A European multicentre drug utilisation study of the impact of regulatory measures on prescribing of codeine for pain in children. / Hedenmalm, Karin (Lead / Corresponding author); Blake, Kevin; Donegan, Katherine; Macia, Miguel Angel; Gil, Miguel; Williams, Julie; Montero, Dolores; Candore, Gianmario; Morales, Daniel; Kurz, Xavier; Arlett, Peter.

In: Pharmacoepidemiology and Drug Safety, 20.06.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A European multicentre drug utilisation study of the impact of regulatory measures on prescribing of codeine for pain in children

AU - Hedenmalm, Karin

AU - Blake, Kevin

AU - Donegan, Katherine

AU - Macia, Miguel Angel

AU - Gil, Miguel

AU - Williams, Julie

AU - Montero, Dolores

AU - Candore, Gianmario

AU - Morales, Daniel

AU - Kurz, Xavier

AU - Arlett, Peter

PY - 2019/6/20

Y1 - 2019/6/20

N2 - Purpose: In June 2013, following recommendations from the World Health Organization (WHO) and Food and Drug Administration (FDA), the European Medicines Agency agreed updates to the codeine product information regarding use for pain in children younger than 12 years and children undergoing tonsillectomy or adenoidectomy (TA) for obstructive sleep apnoea. This study was conducted to (a) assess effectiveness of these measures on codeine prescribing in the “real-world” setting and (b) test feasibility of a study using a common protocol by regulators with access to databases.Methods: The study was performed using BIFAP (Spain), CPRD (UK), and IMS® Disease Analyzer (France and Germany) databases. Prescribers included general practitioners (GPs) (France and UK), GPs and paediatricians together (Spain), and GPs, paediatricians, and ear, nose, and throat (ENT) specialists separately (Germany). Between January 2010 and June 2015, prevalence of codeine prescribing was obtained every 6 months, and a time series analysis (joinpoint) was performed. Codeine prescribing within ±30 days of TA was also identified. Furthermore, doses, durations, and prior prescribing of other analgesics were investigated.Results: Over the 5-year period, codeine prescribing decreased in children younger than 12 years (by 84% in France and Spain, 44% in GP practices in Germany, and 33% in the United Kingdom). The temporal pattern was compatible with the regulatory intervention in France and the United Kingdom, whereas a decrease throughout the study period was seen in Germany and Spain. Decreased prescribing associated with TA was suggested in ENT practices in Germany.Conclusions: Codeine prescribing for children decreased in line with introduced regulatory measures. Multidatabase studies assessing impact of measures by EU regulators are feasible.

AB - Purpose: In June 2013, following recommendations from the World Health Organization (WHO) and Food and Drug Administration (FDA), the European Medicines Agency agreed updates to the codeine product information regarding use for pain in children younger than 12 years and children undergoing tonsillectomy or adenoidectomy (TA) for obstructive sleep apnoea. This study was conducted to (a) assess effectiveness of these measures on codeine prescribing in the “real-world” setting and (b) test feasibility of a study using a common protocol by regulators with access to databases.Methods: The study was performed using BIFAP (Spain), CPRD (UK), and IMS® Disease Analyzer (France and Germany) databases. Prescribers included general practitioners (GPs) (France and UK), GPs and paediatricians together (Spain), and GPs, paediatricians, and ear, nose, and throat (ENT) specialists separately (Germany). Between January 2010 and June 2015, prevalence of codeine prescribing was obtained every 6 months, and a time series analysis (joinpoint) was performed. Codeine prescribing within ±30 days of TA was also identified. Furthermore, doses, durations, and prior prescribing of other analgesics were investigated.Results: Over the 5-year period, codeine prescribing decreased in children younger than 12 years (by 84% in France and Spain, 44% in GP practices in Germany, and 33% in the United Kingdom). The temporal pattern was compatible with the regulatory intervention in France and the United Kingdom, whereas a decrease throughout the study period was seen in Germany and Spain. Decreased prescribing associated with TA was suggested in ENT practices in Germany.Conclusions: Codeine prescribing for children decreased in line with introduced regulatory measures. Multidatabase studies assessing impact of measures by EU regulators are feasible.

KW - children

KW - codeine

KW - drug utilization

KW - pharmacoepidemiology

KW - risk minimization measures

UR - http://www.scopus.com/inward/record.url?scp=85067841414&partnerID=8YFLogxK

U2 - 10.1002/pds.4836

DO - 10.1002/pds.4836

M3 - Article

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

ER -